Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6595709 | 0.99 | ALDH1A1 (0.38) | ALDH1A1LMNAKDM4ESMN1; SMN2HTT | |
| Hydrochloric Acid SCHEMBL1194173 | 0.92 | ALDH1A1 (0.37) | ALDH1A1LMNAKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL6598073 | 0.91 | ALDH1A1 (0.38) | ALDH1A1LMNAKDM4ESMN1; SMN2KMT2A | |
| Hydrochloric Acid SCHEMBL1194171 | 0.89 | ACHE (0.32) | ALDH1A1LMNAKDM4E | |
| SCHEMBL6599195 | 0.88 | ACHE (0.32) | ALDH1A1LMNAKDM4E | |
| Hydrochloric Acid SCHEMBL1193915 | 0.84 | KMT2A (0.35) | ALDH1A1LMNAKDM4ESMN1; SMN2HTT | |
| SCHEMBL6596187 | 0.83 | KMT2A (0.35) | ALDH1A1LMNAKDM4ESMN1; SMN2HTT | |
| SCHEMBL6596014 | 0.83 | KMT2A (0.47) | ALDH1A1LMNAKDM4ESMN1; SMN2HTT | |
| Hydrochloric Acid SCHEMBL1194170 | 0.82 | — | — | |
| Bromide SCHEMBL1193597 | 0.82 | KMT2A (0.49) | ALDH1A1LMNAKDM4ESMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2659933-A1 | Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc. | Torrent Pharmaceuticals Ltd. (IN) | 2013-11-06 | — | — | EP | claimed |
| JP-2011510067-A | — | — | 2011-03-31 | — | — | JP | claimed |
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | TORRENT PHARMACEUTICALS LTD. (IN) | 2011-02-10 | — | — | US | claimed |
| EP-2254563-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING SPECIFIED AGE BREAKER AND FURTHER DRUGS, I.A. ANTIHYPERTENSIVE DRUGS, ANTIDIABETIC DRUGS ETC | Torrent Pharmaceuticals Ltd. (IN) | 2010-12-01 | — | — | EP | claimed |
| WO-2009093264-A2 | PHARMACEUTICAL COMBINATIONS | TORRENT PHARMACEUTICALS LTD. (IN) | 2009-07-30 | — | — | WO | claimed |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2007-07-19 | — | — | US | claimed |
| US-7223777-B2 | Compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-05-29 | — | — | US | claimed |
| EP-1373263-B1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | TORRENT PHARMACEUTICALS LTD (IN) | 2004-10-27 | — | — | EP | claimed |
| WO-2002085897-A9 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2004-04-01 | — | — | WO | claimed |
| EP-1373263-A1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | Torrent Pharmaceuticals Ltd (IN) | 2004-01-02 | — | — | EP | claimed |
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-03-06 | — | — | US | claimed |
| WO-2002085897-A1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2002-10-31 | — | — | WO | claimed |
| EP-2659933-A1 | Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc. | Torrent Pharmaceuticals Ltd. (IN) | 2013-11-06 | — | — | EP | disclosed |
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | TORRENT PHARMACEUTICALS LTD. (IN) | 2011-02-10 | — | — | US | disclosed |
| EP-2254563-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING SPECIFIED AGE BREAKER AND FURTHER DRUGS, I.A. ANTIHYPERTENSIVE DRUGS, ANTIDIABETIC DRUGS ETC | Torrent Pharmaceuticals Ltd. (IN) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009093264-A2 | PHARMACEUTICAL COMBINATIONS | TORRENT PHARMACEUTICALS LTD. (IN) | 2009-07-30 | — | — | WO | disclosed |
| WO-2002085897-A9 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2004-04-01 | — | — | WO | disclosed |
| EP-1373263-A1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | Torrent Pharmaceuticals Ltd (IN) | 2004-01-02 | — | — | EP | disclosed |
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-03-06 | — | — | US | disclosed |
| WO-2002085897-A1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | ALDH1A1 132/4885LMNA 641/4885KDM4E 639/4885 |
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | AGER, F12, DPP4 | ALDH1A1 528/4885LMNA 818/4885KDM4E 1646/4885 |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | ALDH1A1 226/4885LMNA 480/4885KDM4E 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.